Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 28 August, 2007

XTL Biopharm Ltd

XTL Receives Staff Letter from NASDAQ


                     XTL Receives Staff Letter from NASDAQ                     
         XTL May Transfer its ADR Listing to the NASDAQ Capital Market         

Valley Cottage, New York, August 28, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL), a biopharmaceutical company engaged in the
acquisition, development and commercialization of therapeutics for the
treatment of unmet medical needs, particularly neuropathic pain and hepatitis
C, today announced the receipt on August 23, 2007, of a NASDAQ Staff Deficiency
Letter indicating that, according to the Company's financial statements for the
six months ended June 30, 2007, XTL no longer complies with the minimum $10
million shareholders' equity requirement for continued listing on The NASDAQ
Global Market as set forth in Marketplace Rule 4450(a)(3).

The Company intends to respond to NASDAQ with information that may enable the
Company to maintain its listing on The NASDAQ Global Market; however, if the
Company's plan for compliance is not satisfactory, the Company has the option
to transfer its ADR listing to the NASDAQ Capital Market, previously called the
NASDAQ SmallCap Market.

The NASDAQ Capital Market is a continuous trading market that operates in the
same manner as The NASDAQ Global Market. The NASDAQ Capital Market is not
related to, nor does it operate similarly to the over-the-counter markets
including the OTCBB and Pink Sheets. Should the Company transfer its ADR
listing to The NASDAQ Capital Market, its trading symbol on NASDAQ would remain
"XTLB," and the Company does not expect any interruption in the trading of its
ADRs.

The NASDAQ Capital Market includes over 500 issuers of a wide range of
capitalization sizes. A NASDAQ Capital Market security satisfies all applicable
qualification requirements for NASDAQ securities, and all companies listed on
The NASDAQ Capital Market must meet certain financial requirements and adhere
to NASDAQ's corporate governance standards.

ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development
and commercialization of therapeutics for the treatment of neuropathic pain and
hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine
reuptake inhibitor, for the treatment of neuropathic pain. XTL is also
developing several novel pre-clinical hepatitis C small molecule inhibitors.
 XTL also has an active in-licensing and acquisition program designed to
identify and acquire additional drug candidates. XTL is publicly traded on the
NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE:
XTL).

Contact:
Ron Bentsur, Chief Executive Officer
Tel: +1-(845)-267-0707 ext. 225
+972-8-930-4444

Cautionary Statement
Some of the statements included in this press release, particularly those
anticipating continued trading of the Company's ADRs on the NASDAQ Global
Market, the potential transfer of trading to the NASDAQ Capital Market, the
expected uninterrupted trading of the ADR, and the Company's ability to comply
with NASDAQ Capital Market listing requirements, may be forward-looking
statements that involve a number of risks and uncertainties. For those
statements, we claim the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform Act of 1995.
Risk factors that could adversely affect our operations are identified from
time to time in our reports filed with the Securities and Exchange Commission
and the London Stock Exchange, including our annual report on Form 20-F filed
with the Securities and Exchange Commission on March 23, 2007. Any
forward-looking statements set forth in this press release speak only as of the
date of this press release. We do not intend to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. This press release and prior releases are available at http://
www.xtlbio.com. The information in our website is not incorporated by reference
into this press release and is included as an inactive textual reference only.

                                                                              2


                                                                                                               

a d v e r t i s e m e n t